Medical Condition News

RSS

ABI therapy effective for treating microtears in hamstring injury: Study

Researchers in London say they have found an effective two-part treatment for microtears in the hamstring: injections of the patient's own blood and a steroid along with "dry-needling," in which repeated needle punctures cause controlled internal bleeding in the injured area. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

Study confirms difference in coronary artery disease pathways among Caucasians, African Americans

In a study being presented today at the annual meeting of the Radiological Society of North America (RSNA), researchers say they may have an explanation as to why African Americans, despite having lower amounts of coronary artery calcification, are at increased risk for heart attacks and other cardiovascular events compared with Caucasians.

30 Nov 2010

New chest X-ray technology enhances lung nodule detection

Riverain Medical, an industry leader and innovator in computer-aided detection (CAD) and advanced visualization technologies, today announced its SoftView Enhanced Chest Imaging and OnGuard Chest X-ray Computer-Aided Detection (CAD) technologies can now integrate In Unison for improved workflow and enhanced lung nodule detection.

30 Nov 2010

Study: Mature blood cells communicate with parent stem cells

A new study by researchers at the Walter and Eliza Hall Institute in Melbourne, Australia, has shown that mature blood cells can communicate with, and influence the behaviour of, their stem cell 'parents'.

30 Nov 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Array BioPharma to present data on ARRY-520 Phase 1 trial for multiple myeloma at ASH Annual Meeting

Array BioPharma Inc. today announced that it will present data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on Saturday, December 4, 2010.

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Scientists discover M3-protein can help maintain blood sugar levels

Medical scientists at the University of Leicester have identified for the first time a new way in which our body controls the levels of sugar in our blood following a meal.

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

More women are dying of lung cancer in UK

New research shows that the rates of lung cancer in women have risen and this could be a sign that efforts to persuade them to quit smoking have failed. The cases among men have fallen on the other hand.

29 Nov 2010

Synthon receives FDA final approval for generic Xyzal

Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.

29 Nov 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

Accuray's CyberKnife VSI System recognized as Best New Radiology Device of 2010

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the company's CyberKnife® VSI™ System received the 2010 Minnie for Best New Radiology Device from AuntMinnie.com, the largest and most comprehensive community internet site for radiologists and related professionals in the medical imaging industry. Accuray will be presented with the award at the 2010 Radiological Society of North America (RSNA) annual meeting taking place in Chicago, Ill. from November 28 – December 3, 2010.

29 Nov 2010

Hemispherx requests FDA time extension for Ampligen NDA data resubmission

Hemispherx Biopharma, Inc., announced that the Company has requested an extension of time in which to resubmit data to its NDA for Ampligen®, an experimental therapeutic, to treat CFS.

29 Nov 2010

Ziosoft announces launch of PhyZiodynamic solutions at RSNA 2010

Ziosoft, Inc., a leader in functional visualization and analytics, will launch its PhyZiodynamic solutions at the Radiology Society of North America (RSNA) being held November 28 – December 3, 2010 in Chicago. PhyZiodynamic solutions represent a generational leap in advanced visualization.

29 Nov 2010

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).

29 Nov 2010

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010